{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=peginterferon+alpha-2a", "query": { "intervention": "peginterferon alpha-2a" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 30, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=peginterferon+alpha-2a&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-14T02:38:58.270Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01289782", "title": "An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Placebo", "type": "DRUG" }, { "name": "TMC435", "type": "DRUG" }, { "name": "Peginterferon alpha-2a (PegIFN alpha-2a)", "type": "DRUG" }, { "name": "Ribavirin (RBV)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen R&D Ireland", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 395, "start_date": "2011-02", "completion_date": "2013-01", "has_results": true, "last_update_posted_date": "2014-06-04", "last_synced_at": "2026-09-14T02:38:58.270Z", "location_count": 22, "location_summary": "Dothan, Alabama • Hoover, Alabama • Phoenix, Arizona + 19 more", "locations": [ { "city": "Dothan", "state": "Alabama" }, { "city": "Hoover", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Bakersfield", "state": "California" }, { "city": "Coronado", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01289782" }, { "nct_id": "NCT01180790", "title": "Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "ACH-0141625 (Sovaprevir)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Pegylated Interferon alpha-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Alexion Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 122, "start_date": "2010-09", "completion_date": "2013-04", "has_results": true, "last_update_posted_date": "2023-08-30", "last_synced_at": "2026-09-14T02:38:58.270Z", "location_count": 15, "location_summary": "Los Angeles, California • San Francisco, California • Bradenton, Florida + 11 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Bradenton", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01180790" }, { "nct_id": "NCT00085917", "title": "Peginterferon Alpha-2a and Ribavirin to Treat Hepatitis C in HIV-infected Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C", "HIV Infections" ], "interventions": [ { "name": "Double dose pegylated interferon with weight based Ribavirin", "type": "DRUG" }, { "name": "standard dose pegylated interferon alfa -2a and ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2004-06", "completion_date": "2008-11", "has_results": true, "last_update_posted_date": "2011-06-27", "last_synced_at": "2026-09-14T02:38:58.270Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00085917" }, { "nct_id": "NCT05535764", "title": "AlloHCT With PegINFa for Myelofibrosis", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Myelofibrosis" ], "interventions": [ { "name": "Pegylated interferon alpha2a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2023-08-02", "completion_date": "2028-03", "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-09-14T02:38:58.270Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT05535764" }, { "nct_id": "NCT01479868", "title": "A Study to Assess the Safety, Tolerability and Efficacy of TMC435 Along With Pegylated Interferon Alpha-2a (Pegasys) and Ribavirin (Copegus) Triple Therapy in Chronic Hepatitis C Genotype-1 Infected Patients Co-infected With Human Immunodeficiency Virus-Type 1", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Hepatitis C Virus Genotype-1" ], "interventions": [ { "name": "TMC435", "type": "DRUG" }, { "name": "Pegylated interferon alpha-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Janssen R&D Ireland", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 109, "start_date": "2011-10", "completion_date": "2013-08", "has_results": true, "last_update_posted_date": "2014-10-29", "last_synced_at": "2026-09-14T02:38:58.270Z", "location_count": 10, "location_summary": "Los Angeles, California • Washington D.C., District of Columbia • Orlando, Florida + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Orlando", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01479868" }, { "nct_id": "NCT00545233", "title": "A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "peginterferon alfa-2a [Pegasys]", "type": "DRUG" }, { "name": "ribavirin [Copegus]", "type": "DRUG" }, { "name": "Pioglitazone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 155, "start_date": "2008-01", "completion_date": "2010-12", "has_results": true, "last_update_posted_date": "2012-05-07", "last_synced_at": "2026-09-14T02:38:58.270Z", "location_count": 65, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 53 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00545233" }, { "nct_id": "NCT00874770", "title": "Safety and Efficacy of Daclatasvir (BMS-790052) Plus Standard of Care (Pegylated-interferon Alpha and Ribavirin)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C Infection" ], "interventions": [ { "name": "Daclatasvir", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Peginterferon alpha-2a", "type": "DRUG" }, { "name": "ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 74, "start_date": "2009-06", "completion_date": "2011-01", "has_results": true, "last_update_posted_date": "2015-10-23", "last_synced_at": "2026-09-14T02:38:58.270Z", "location_count": 11, "location_summary": "Montgomery, Alabama • Aurora, Colorado • New Haven, Connecticut + 7 more", "locations": [ { "city": "Montgomery", "state": "Alabama" }, { "city": "Aurora", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Springfield", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00874770" }, { "nct_id": "NCT06471673", "title": "A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer", "Breast Tumor", "Cancer of Breast", "Cancer of the Breast", "Malignant Tumor of Breast", "Tumors, Breast" ], "interventions": [ { "name": "BC1 cell line", "type": "BIOLOGICAL" }, { "name": "Bria-OTS regimen and CPI (tislelizumab)", "type": "BIOLOGICAL" }, { "name": "Bria-OTS regimen and CPI (tislelizumab) expansion cohort", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "BriaCell Therapeutics Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2024-05-29", "completion_date": "2025-10-30", "has_results": false, "last_update_posted_date": "2024-08-26", "last_synced_at": "2026-09-14T02:38:58.270Z", "location_count": 1, "location_summary": "Santa Monica, California", "locations": [ { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06471673" }, { "nct_id": "NCT00023322", "title": "Pegylated Interferon to Treat Chronic Hepatitis D", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis D" ], "interventions": [ { "name": "Peginterferon Alpha-2a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2001-08", "completion_date": "2012-10", "has_results": true, "last_update_posted_date": "2013-07-10", "last_synced_at": "2026-09-14T02:38:58.270Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00023322" }, { "nct_id": "NCT00594880", "title": "Antiviral Activity of Peg-IFN-Alpha-2A in Chronic HIV-1 Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections" ], "interventions": [ { "name": "Pegylated Interferon-alpha 2a, 180 mcg/week sc", "type": "DRUG" }, { "name": "Pegylated Interferon-alpha 2a, 90 mcg/week sc", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "The Wistar Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 23, "start_date": "2008-01", "completion_date": "2011-05", "has_results": true, "last_update_posted_date": "2015-02-10", "last_synced_at": "2026-09-14T02:38:58.270Z", "location_count": 5, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00594880" } ] }